

## Projects & Committees

### **FluidIQ**

#### **HOPE Ventilator Project**

**May 2020 - current**

Executive Program Member

The goal of this project is the development and deployment of a novel ventilator. Provide insights on funding opportunities relevant to the company's efforts to develop devices and fund its operations. Identify knowledge leaders and develop an outreach plan.

#### **Digital Clinical Trials in fibrotic interstitial lung disease**

**April 2020 - current**

Co-Organizer and Senior Project Manager

The goal of this project is to evaluate the effectiveness and validity of e-Health visits in fibrotic interstitial lung disease. Expanding clinical trial opportunities for those patients that may have difficulty participating due to travel restrictions or fearful of putting themselves and loved ones at risk during the COVID-19 pandemic. To evaluate if this methodology of decentralized clinical trials improves the research experience for patients and their care team.

#### **ARMEE Ventilator Project**

##### **Interstate Disaster Medical Collaborative**

**March 2020 – May 2020**

Volunteer Project Member

The overall goal of the project is to provide insights on research and funding opportunities relevant to the Interstate Disaster Medical Collaborative (IDMC) to further its development of a scalable, portable 3D printed ventilator. The ARMEE™ ventilation device (ARMEEVent.com) which stands for "Automatic Respiration Management Exclusively for Emergencies" is based on technology developed in the 1960s by Harry Diamond Laboratories for the U.S. Army. Experts believe the simply-designed ventilator, which requires no electricity and has no moving parts, represents an economical, rapidly deployable ventilation tool that can be utilized in almost any kind of emergency, disaster response or in under-served countries.

### **Magnolia Therapeutics**

**August 2018**

Consultant Advisor

Provide insights on funding opportunities and identify potential sources of biologic specimens relevant to the company's efforts to develop products in fibrotic lung disease and other rare diseases. Develop an idiopathic pulmonary fibrosis educational program and patient forum for the company's staff.

#### **The Fibrosis-Cancer Connection: A Comparative Workshop**

**January 2015 – 2016**

Senior Project Management

Co-Organizer

The goal of this scientific workshop is to facilitate the advancement of research efforts in the fibrosis-cancer connection; leading to improvement of patients' lives who suffer from pulmonary fibrosis (PF) and cancer, PF patients who are at risk for cancer as well as cancer survivors who have or are at risk of developing PF.

## Projects & Committees

### **FDA Patient Focused Drug Development**

**September 2014**

Senior Project Manager

Organizer

Assist the Pulmonary Fibrosis Foundation and its representatives and patient advocates in preparation of testimony to the FDA in support of approval of therapeutic products under review.

### **IPF Guidance for Industry**

**September 2014**

Senior Project Manager

Organizer

Facilitate development of IPF Guidance for Industry, act as liaison between FDA, PFF, NIH, patient and caregivers, and additional collaborators. Facilitate development of working groups and moderate and host meetings on behalf of the PFF. The goal of the guidance is to encourage the FDA and trial sponsors to engage patients and their families at all stages of trial development and to take into account what they consider acceptable risk in clinical trials. Each section of the guidance will include extensive published or in-press peer-reviewed articles and focus on specific areas aimed at overcoming the challenges in trial design and implementation.

### **Webinar: EXPLORE IPF Survey**

**February 2015 - March 2015**

Presenter

This webinar shared findings from EXPLORE IPF, a survey sponsored by Boehringer Ingelheim and led by a multidisciplinary Advisory Committee of thought leaders and advocates dedicated to addressing the unmet needs of the idiopathic pulmonary fibrosis (IPF) community. The EXPLORE IPF survey shines a light on the emotional and physical toll of IPF and offers recommendations on the education and support services available to people with IPF and their caregivers.

### **Mile High Pulmonary Fibrosis Support Group**

**Fun Run/Walk and Community Health Fair**

**Lutheran Medical Center Foundation**

**February 2015 – September 2015**

**Organizer and Steering Committee Member**

### **Fibrosis Across Species Workshop: A Workshop on Comparative Pathobiology of Fibrosing Lung Disorders**

**January 2013 – 2019 (publication)**

Senior Project Manager

The Fibrosis Across Species effort included a workshop on comparative pathobiology of fibrosing lung disorders to gather physicians and veterinary experts, pathologists, community advocates, and representatives of private foundations, industry, biotechnology, and federal scientific organizations. The workshop was designed to advance knowledge in the area of lung fibrosis in humans and domestic animals and in particular, in breeds of terrier dogs such as the West Highland White Terrier and in thoroughbred horses.

## Projects & Committees

### **Patient Participation Program for Pulmonary Fibrosis: Assessing the Effects of Supplemental Oxygen Patient Centered Outcomes Research Institute (PCORI) Research Grant**

**July 2013 – 2018 (publications)**

Steering Committee Member

The overall objective of the project is to enhance understanding of supplemental oxygen, its utility in and adoption by PF patient; by examining how PF patients perceive it and by determining how those perceptions and several things important to patients (such as symptoms, quality of life, activity levels) change from before to after supplemental oxygen is prescribed. To conduct this research, we will identify patients with PF who are willing to participate in research. Enroll patients with PF into the study and perform interviews and/or a one-year study of supplemental oxygen.

### **PFF Summit 2015**

**January 2014 – 2015**

Senior Project Manager

Organizing Committee Member

Facilitate educational content development, organizing committee meetings, logistics and facility support, CME provider and A/V production management. The PFF Summit 2015 is a unique venue that brings together patients, caregivers, health care professionals, governmental agencies and industry representatives dedicated to finding a treatment and a cure for PF.

### **EXPLORE IPF Survey: Insights into the Lives of People with IPF and their Caregivers**

**November 2013 - October 2014**

Advisory Committee Member

The EXPLORE IPF survey investigated the needs, experiences and feelings of patients living with Idiopathic Pulmonary Fibrosis (IPF) and their caregivers. It was led by a multidisciplinary Advisory Committee that includes IPF thought leaders and advocates dedicated to addressing the unmet needs of the IPF community. The survey was conducted among 100 patients with IPF and 100 caregivers, all self-reported.

### **American Thoracic Society (ATS) Breathing Better Advocacy Alliance**

**September 2012 - Current**

Steering Committee Member

### **American Thoracic Society Fibrosis Across Organs Symposium**

**July 2010 – 2019 (publication)**

Organizing Committee Member

8-11 March 2012

Denver, Colorado

The meeting's objectives were to set the scientific priorities for future investigations in single organ and cross-organ fibrotic disease, assess the currently available experimental models and their relevance to human health and disease and to identify potential promising therapies for pathologic tissue fibrosis, including idiopathic pulmonary fibrosis (IPF), also referred to as simply pulmonary fibrosis (PF) or lung fibrosis and fibrosis that occurs in the heart, liver, kidney and skin.

## Projects & Committees

### **Pulmonary Fibrosis Foundation Medical Advisory Board**

**March 2011 – December 2014**

Senior Project Manager

Consult on organization and structure of medical advisory board, facilitate executive committee meetings and working groups of the Board.

### **Pulmonary Fibrosis Foundation Support Group Expansion**

**March 2011 – December 2014**

Senior Project Management

Expand and enhance the PFF patient support group and leadership network.

### **Electronic Sponsorship Application Process – Pulmonary Fibrosis Foundation**

**September 2014 – December 2014**

Senior Project Management

Lead the development of an electronic application process for educational sponsorship requests to the Pulmonary Fibrosis Foundation.

### **Pulmonary Fibrosis Foundation Patient and Caregiver Survey**

**July 2014 – December 2014**

PFF Medical Affairs Project Team Member

### **Global PF Awareness Month 2014**

**October 2013 – December 2014**

Organizing Committee Member

September was designated Global Pulmonary Fibrosis Awareness Month. Campaign to bring awareness to Pulmonary Fibrosis were held world-wide.

### **Pulmonary Fibrosis Foundation Patient Communication Center**

**2012 - 2014**

Director and Senior Project Manager

### **Pulmonary Fibrosis Patient Ambassador Program**

**July 2014**

Senior Project Manager

The purpose of the PFF Ambassador program is to engage with the larger community and cover all aspects of disease education. PFF Ambassadors will share their journey in order to inform and enhance disease awareness with the general public.

### **Pulmonary Fibrosis Patient Education Series**

**February 2013 – November 2013**

Senior Project Manager and Editor

Pulmonary Fibrosis Patient Education Webinar and Video Series: What is Pulmonary Fibrosis

## Projects & Committees

### **PFF Summit from Bench to Bedside 2013**

**January 2012 – December 2013**

Senior Project Manager

Organizing Committee Member

Moderator: Patient and Caregiver Session

The PFF Summit 2013 is a unique venue that brings together a multi-faceted group of physicians, researchers, allied health professionals, industry representatives, patients, and caregivers. The Summit creates a spirit of collaboration in an environment in which the most up-to-date medical information is disseminated with a primary goal of improving the care, management and quality of life for patients and their families. More than 50 world- renowned experts will participate in a variety of activities, which include lectures, facilitated panel discussions, poster presentations, and a “Meet the Experts” session

### **Pulmonary Fibrosis Foundation Patient Care Center Network and Patient Registry**

**2012 - 2014**

Director

Senior Project Manager

Working with stakeholders in the PF community to establish the PFF Care Center Network, where those in the PF community can find expert clinicians skilled in the disease and support.

### **Global PF Patient Education Day 2013 Symposia**

**January 2013 – October 2013**

Senior Project Manager

Organizing Committee Member

Presenter

Patient education symposia for patients, caregivers, and health care professionals affected by pulmonary fibrosis. This live educational event was held on September 7, 2013 in Barcelona, Spain and was broadcast via webcast in multiple languages world-wide. Pulmonary fibrosis experts from Hospital de La Princesa, Madrid, Spain, Hospital Universitario de Bellvitge, Barcelona, Spain, Hospital Vall d’Hebron, Barcelona, Spain, European Organization for Rare Diseases, Barcelona, Spain, Hospital Clinic de Barcelona, Barcelona, Spain, Asociación de Familiares y Enfermos de FPI y FPF (Fibrosis Pulmonar Familiar), Spain, and the Pulmonary Fibrosis Foundation provided up to date educational information to attendees.

### **Global Pulmonary Fibrosis Awareness Day 2013**

**January 2013 – October 2013**

Organizing Committee Member

Organizing and partnering with the global PF community to raise awareness about pulmonary fibrosis.

## Projects & Committees

### **Pulmonary Fibrosis Patient Support Day, Nottingham, England**

**July 2013**

Senior Project Manager

Organizing Committee Member

Presenter

The Pulmonary Fibrosis Foundation and the British Association for Lung Research (BALR) sponsored a special "Pulmonary Fibrosis Patient Support Day" following the BALR Summer Meeting 2013 in Nottingham, England. The patient education event focused on living with pulmonary fibrosis and included reviews of clinical trials, treatment options, disease management, and an update on the NICE guidelines.

### **Support Group Leader Workshop, Modena, Italy 2012**

**September 2012**

Senior Project Manager

Organizing Committee Member Presenter

Support Group Leader Workshop at the University of Modena and Reggio Emilia, Modena, Italy 29 September 2013

To facilitate the expansion and creation of PF support groups globally the PFF hosted a Support Group Leader Workshop in conjunction with the International Colloquium of Lung and Airway Fibrosis (ICLAF) on 29 September 2012 in Modena, Italy.

### **Global Pulmonary Fibrosis Awareness Symposia Modena, Italy September 22, 2012**

**September 2012**

Senior Project Manager

Organizing Committee Member

Presenter

Living Better with Pulmonary Fibrosis

Patient education symposia for patients, caregivers, and health care professionals affected by pulmonary fibrosis. This live educational event was held on 22 September 2010 at the Aula Magna Faculty of Law, Via San Geminiano 3, Modena, Italy, was broadcast via webcast in multiple languages world-wide.

### **IPF Summit 2011 - From Bench to Bedside**

**September 2010 – December 2011**

Organizing Committee Member

Moderator: Patient and Caregiver Session

The IPF Summit 2011 was a two-day continuing medical education program for physicians, researchers, registered nurses, and allied health professionals. A separate two-day program for patients, family members, and caregivers was also held to address the growing educational needs of the pulmonary fibrosis (PF) community.

### **Idiopathic Pulmonary Fibrosis Leadership Summit on Appropriate Endpoints for Phase III Trials**

**July 2011**

Senior Project Manager

Organizing Committee Member

11-12 July 2011

Bethesda, MD

## Projects & Committees

### **Pulmonary Fibrosis Foundation Research Program**

**2011 -2014**

Senior Project Manager

### **Familial Pulmonary Fibrosis Genetic Counseling Program**

**2007 - 2011**

Program Founder and Director

The Program provided telephonic Genetic Counseling from Certified Genetic Counselors to patients and family members with fibrotic lung diseases.

### **Interstitial Lung Disease Database and Bio-repository**

**1992 - 2011**

ILD Database and Repository Manager and Director, National Jewish Health

The ILD database and biospecimen repository began collecting specimens in 1982. The Repository underwent a complete revision under Dolly's direction implementing a bar code system that assisted in linking the repository with the ILD database and registry. This system was the model for the Institutional biospecimen repository at National Jewish as well as other large repositories, including NIH projects tasked with collection and storage of biospecimens and connected data.

### **Genetics of Pulmonary Fibrosis Advisory Committee Meeting**

Senior Project Management & Organizer

7–8 June 2010 Red Rocks, Colorado

Project Manager and Organizing Committee Member

### **Fibrogen: FG3019 Safety and Tolerability Study of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis**

**2003 - 2007**

Advisory Committee

Study Protocol Member

### **National Jewish Health Research Database & Bio-repository Organizing Committee**

**2010 - 2011**

Planning Committee Member

Establish an Institutional coded / anonymized biospecimen repository that serves researchers with access to biologic specimens and associated clinical data relevant to their research interests. Assisting researchers apply for grants and also learn more about their areas of interest and publish important information in peer reviewed journals.

### **National Institutes of Health: Idiopathic Pulmonary Fibrosis Research Network (IPFnet)**

**2005 - 2011**

Advisory Committee

Performance Committee Member

Clinical Research Coordinator Network Chair

Projects & Committees
<p><b>National Jewish Health: Pulmonary Fibrosis Patient Education Day</b></p> <p><b>2008</b>            Project Manager and Organizer            21 November 2008            Denver, Colorado</p>
<p><b>Actelion: A Double Blind, Randomized, placebo Controlled, Multi-center Study to Assess the Efficacy, Safety and Tolerability of Bosentan in patients with Idiopathic Pulmonary Fibrosis.</b></p> <p><b>2006 - 2008</b>            Advisory Committee Member</p>
<p><b>InterMune: Safety and Efficacy of Subcutaneous gamma 1b in IPF</b></p> <p><b>2000 - 2004</b>            Advisory Committee            Chairman, Study Coordinator Advisory Committee</p>
<p><b>Biogen: Interferon Beta-1A in the Treatment of IPF</b></p> <p><b>1998 - 2002</b>            Advisory &amp; Protocol Committee Member            Expert Consultant: Broncho-alveolar Lavage (BAL) Protocol Guidance</p>

Clinical Trial Participation and Coordination
ACE: Anticoagulant Effectiveness in IPF
Artemis-IPF, Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
BUILD1: A Double Blind, Randomized, placebo Controlled, Multi-center Study to Assess the Efficacy, Safety and Tolerability of Bosentan in patients with Idiopathic Pulmonary Fibrosis.
C97-829: Efficacy of Avonex in the Treatment of Idiopathic Pulmonary Fibrosis
COMET: Correlating Outcomes with Biochemical Markers to Estimate Time-progression In IPF
FG3019: Safety and Tolerability Study of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis
FGCL-MC3019-002: A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects with Idiopathic Pulmonary Fibrosis
GIPF001: A Randomized, Double Blind, Placebo Controlled , Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon gamma 1b in Patients with IPF
GIPF002: A Phase II Randomized, Double blind, Placebo Controlled Study of the Safety, Biology and Clinical Effects of Interferon gamma Administered Subcutaneously to Patients with Idiopathic Pulmonary Fibrosis.
GIPF004: An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon gamma –1b in Patients with IPF



Clinical Trial Participation and Coordination
GIPF006: An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon gamma –1b in Patients with IPF
Investigator Initiated Trial: Interferon alpha 2a Treatment Trial in LAM
National Institutes of Health, A Linkage and Association Study in Pulmonary Fibrosis
National Institutes of Health, LAM Registry
National Institutes of Health, Lung Involvement in Systemic Sclerosis: The Role of Inflammation in Pathogenesis
National Institutes of Health, Scleroderma Lung Study (SLSI), Oral Cyclophosphamide vs Oral Placebo in Systemic Sclerosis Pulmonary Alveolitis
National Institutes of Health, Specialized Center of Research in IPF
National Jewish Health, Registry and Repository, Pathobiology of Pulmonary Fibrosis
PANTHER: Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients with IPF
Pulmonary Rehabilitation for IPF
STEP: Sildenafil Trial of Exercise Performance in IPF

Professional Presentations
<p>March 2017 – December 2017            Bayer Healthcare, USA            87 Key opinion leader (KOL) introductory and investigational product presentations at academic institutions            Nationwide, USA</p>
<p>January 2016 – November 2016            Promedior,            48 Clinical research presentations at site initiation visits, investigational product presentations, and KOL visits            Global (EU &amp; USA)</p>
<p>14, 15 January 2016            Promedior, IPF Investigator Meeting            Protocol Summary Review: A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with IPF            Fort Lauderdale, Florida</p>
<p>13 January 2016            Promedior, CRA-Vendor Meeting            Presenter: Disease Education-Idiopathic Pulmonary Fibrosis            Fort Lauderdale, Florida</p>
<p>28 February 2015            Boehringer Ingelheim            Webinar Presenter: EXPLORE IPF Survey - Insights into the Lives of People with IPF and their Caregivers  <a href="https://www.youtube.com/watch?v=4pXU16LXeCY&amp;feature=youtu.be">https://www.youtube.com/watch?v=4pXU16LXeCY&amp;feature=youtu.be</a></p>
<p>27 October 2014            Session Moderator: Explore IPF Survey - Understanding the Patient and Caregiver Experience            CHEST 2014: American College of Chest Physicians Meeting – Disease Theater            Austin, Texas</p>

## Professional Presentations

21 September 2014

[International Colloquium on Lung and Airway Fibrosis \(ICLAF\)](#)

Presenter: Roundtable Advocacy in IPF - Pulmonary Fibrosis Foundation Patient Survey Results  
Mont-Tremblant, Quebec, Canada

24 June 2014

University of Washington Pulmonary Fibrosis Support Group Meeting

Presenter: Pulmonary Fibrosis Foundation Programs and Support Services  
Seattle, Washington

9 April 2014

British Lung Foundation

Presenter: Pulmonary Fibrosis Foundation Programs and Services  
London, United Kingdom

19 March 2014

University of Kentucky PF Patient Support Group Meeting

Presenter: Advocacy and Awareness for Pulmonary Fibrosis  
Louisville, Kentucky

18 February 2014

Genentech Inc.

Presenter: Pulmonary Fibrosis Foundation Patient Services and Care Center Network/Registry Program  
South San Francisco, California

10 February 2014

Breath Matters Support Group Meeting

Presenter: Pulmonary Fibrosis Foundation Patient Services  
Richmond, Virginia

7 September 2013

Global Pulmonary Fibrosis Awareness 2013

Presenter: Living with Pulmonary Fibrosis and the Role of Support Groups  
Barcelona, Spain

27 August 2013

Pulmonary Fibrosis Foundation Town Hall Meeting

Presenter: PFF Patient Services  
Chicago, Illinois

31 July 2013

InterMune, Inc

Presenter: Pulmonary Fibrosis Foundation Patient Services and Care Center Network/Registry Program  
Brisbane, California

13 July 2013

British Association for Lung Research (BALR)

Pulmonary Fibrosis Patient Support Day

Presenter: Pulmonary Fibrosis Foundation Programs and Services  
Nottingham, United Kingdom

8 July 2013

British Lung Foundation

Presenter: Pulmonary Fibrosis Foundation Programs and Services  
London, United Kingdom

15 May 2013

University of Utah: Best Practices in Caring for Patients with IPF

Presenter: Pulmonary Fibrosis Advocacy and Patient Services  
Salt Lake City, Utah

24 April 2013

National Organization or Rare Disorders

Regional Membership Meeting

Presenter: Pulmonary Fibrosis Foundation Research Grant Program  
Chicago, Illinois

## Professional Presentations

<p>26 March 2013            University of Washington Pulmonary Fibrosis Support Group Meeting            Presenter: Pulmonary Fibrosis Foundation Programs and Support Services            Seattle, Washington</p>
<p>3 December 2012            Bristol-Myers Squibb            Presenter: Pulmonary Fibrosis Foundation Services and Care Center Network/Registry Project            Chicago, Illinois</p>
<p>22 September 2012            Global Pulmonary Fibrosis Awareness 2012            Presenter: Living with Pulmonary Fibrosis and the Role of Support Groups            Modena, Italy</p>
<p>29 September 2012            Pulmonary Fibrosis Support Group Leader Workshop            Presenter: Creating Effective Support Groups            Modena, Italy</p>
<p>1-3 December 2011            IPF Summit 2011: Bench to Bedside            Moderator: Patient and Caregiver Program Sessions            1-3 December 2011            Chicago, Illinois</p>
<p>19 November 2011            Wheat Ridge Colorado PF Support Group Meeting            Presenter: Advocacy and Awareness Update            Wheat Ridge, Colorado</p>
<p>14 November 2011            University of Kentucky PF Patient Support Group Meeting            Presenter: Advocacy and Awareness for Pulmonary Fibrosis            Louisville, Kentucky</p>
<p>16 June 2011            University of Utah PF Patient Support Group Meeting            Presenter: Pulmonary Fibrosis Advocacy and Patient Services            Salt Lake City, Utah</p>
<p>16 April 2011            Colorado Respiratory Therapy Student Education            Presentation: Interstitial Lung Disease            Wheat Ridge, Colorado</p>
<p>2005 -2011            Idiopathic Pulmonary Fibrosis Research Network            Presenter: Performance and Research Coordinator Training and Committee Reporting            Network Advisory Committee Meetings – Quarterly Meetings</p>
<p>29 September 2009            Wheat Ridge Colorado PF Support Group Meeting            Presenter: Advocacy and Awareness Update            Wheat Ridge, Colorado</p>
<p>21 November 2008            Presenter &amp; Moderator            Pulmonary Fibrosis Patient Education Day            National Jewish Health, Denver CO</p>
<p>17 March 2007            Idiopathic Pulmonary Fibrosis Research Network            Presenter: IPFnet Investigator Meeting – STEP Protocol            17 March 2007            Chicago, Illinois</p>

## Professional Presentations

24 October 2006  
University of Utah PF Patient Support Group Meeting  
Presenter: Pulmonary Fibrosis Advocacy and Patient Services  
Salt Lake City, Utah

## Publications

Roman J, Barnes TR, **Kervitsky DJ**, et al. The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities. *Am J Med Sci*. 2019;357(5):405-410. doi:10.1016/j.amjms.2019.02.014

Teresa Barnes, BS, Kevin K. Brown, MD, Brendan Corcoran, MVD, DipPharm, PhD, MRCVS, Marilyn K. Glassberg, MD, **Dolly J. Kervitsky, RCP**, Andrew H. Limper, MD<sup>6</sup>, Kay McGuire, DVM, MS, Kurt Williams, DVM, PhD and Jesse Roman, MD. Research in Pulmonary Fibrosis Across Species: Unleashing Discovery Through Comparative Biology *Am J Med Sci* 2019;357(5):399-404

Albright K, Walker T, Baird S, Eres L, Farnsworth T, Fier K, **Kervitsky D**, Korn M, Lederer DJ, McCormick M, Steiner JF, Vierzba T, Wamboldt FS, Swigris JJ. Seeking and sharing: why the pulmonary fibrosis community engages the web 2.0 environment. *BMC Pulm Med* 2016 Jan 12;16:4 doi: 10.1186/s12890-016-0167-7.

**Kervitsky Dolly (Alma) J**, The Respiratory Therapist's Role in Recognizing Pulmonary Fibrosis. *AARC Times* June 2015

John F P Bridges, Victoria Federico Paly, Elizabeth Barker, **Dolly Kervitsky**: Identifying the Benefits and Risks of Emerging Treatments for Idiopathic Pulmonary Fibrosis: A Qualitative Study *The Patient* 31 July 2014 DOI 10.1007/s40271-014-0081-0

**IPFnet Investigators**, De Andrade J, Schwarz M, Collard H, The idiopathic pulmonary fibrosis clinical research network (IPFnet): Diagnostic and adjudication processes. *Chest* 2015 Volume 148 issue 4: 1034-1042

**IPFnet Investigators**, Swigris J, Steiner D, Brown K, Belkin A, Green, KA, Wamboldt F, Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis *Respiratory Medicine* 2014, 108(1) 181-188

**IPF Clinical Research Network**, Martinex FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. *N Engl J Med*. 2014 May 29;370(22):2093-101. Doi: 10.1056/NEJMoq1401739. Epub 2014 May 18

S.L. Schmidt, M.K. Han, N. Tayob, C. Zappala, **D. Kervitsky**, S. Murray, G. Toews, F.J. Martinez, A.U. Wells, K.K. Brown, K.R. Flaherty: Idiopathic Pulmonary Fibrosis: Predicting Future Disease Course From Past Trends In Pulmonary Function. *Chest*. 2014 Mar 1;145(3):579-85. doi: 10.1378/chest.13-0844

**IPFnet Investigators**, Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials *Respir Res*. 2013 Jul 13;14:73. Doi 10.1186/1465-9921-14-73.

Yang IV, Luna LG, Cotter J, Talbert J, Leach SM, Kidd R, Turner J, Kummer N, **Kervitsky D**, Brown KK, Boon K, Schwarz MI, Schwartz DA, Steele MP. The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis *PLoS One*. 2012;7(6):e37708. Epub 2012 Jun 22.

**IPF Clinical Research Network**, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis *N Engl J Med* 2012 May 24;366(21): 1968-77. Doi. 1056?NEJMoa1113354. Epub 2012 May 20.

Mark P. Steele, Kevin K. Brown, James E. Loyd, Tasha Fingerlin, Max A. Seibold, Nathan Kummer, **Dolly Kervitsky**, Janet Talbert, Raven Kidd, Cheryl Markin, Marvin I. Schwarz, David A. Schwartz The Environment Influences the Risk of Developing Familial Interstitial Pneumonia. *Am J Respir Crit Care Med* 183;2011:A5690

## Publications

Gregory P. Cosgrove, Steve Groshong, Janet Talbert, **Dolly Kervitsky**, Ryan Delaney, Nathan Kumer, Cheryl Markin, Raven Kidd, Carlyne Cool, Max Seibold, Mark Steele, James E. Loyd, Kevin K. Brown, David A. Schwartz, Marvin I. Schwarz: Familial Interstitial Pneumonia (FIP) is Similar Pathologically to Idiopathic Interstitial Pneumonia. *Am J Respir Crit Care Med* 183;2011:A2332

S.L. Schmidt, M.K. Han, N. Tayob, C. Zappala, **D. Kervitsky**, S. Murray, G. Toews, F.J. Martinez, A.U. Wells, K.K. Brown, K.R. Flaherty: Idiopathic Pulmonary Fibrosis: Predicting Future Disease Course From Past Trends In Pulmonary Function. *Am J Respir Crit Care Med* 183;2011:A5299 (abstract)

Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD, Evans CM, Garantziotis S, Adler KB, Dickey BF, du Bois RM, Yang IV, Herron A, **Kervitsky D**, Talbert JL, Markin C, Park J, Crews AL, Slifer SH, Auerbach S, Roy MG, Lin J, Hennessy CE, Schwarz MI, Schwartz DA. A Common MUC5B Promoter Polymorphism is Associated with Pulmonary Fibrosis *N Engl J Med.* 2011 Apr 21;364(16):1503-12..

**LAM Network:** Efficacy and Safety of Sirolimus in Lymphangiomyomatosis. *N Engl J Med* 2011 Apr 28;364(17):1595-606. Doi: 10.1056/NEJMoa1100391. Epub 2011 Mar 16.

M.A. Seibold, PhD, J. Lin, BS, **D. Kervitsky, CRT, CCRC**, J. Wescott, PhD, N. Kummer, BS, E. Murphy, MS, J. Talbert, MS, M.P. Steele, MD, J.E. Loyd, MD<sup>3</sup>, K.K. Brown, MD, M.I. Schwarz, MD, R.M. du Bois, MD, D.A. Schwartz, MD: The concentration of MUC5AC is higher in the air space of idiopathic pulmonary fibrosis (IPF) subjects and is associated with a disease susceptibility variant (Ala497Val) in MUC5AC *Am J Respir Crit Care Med* 181;2010:A2493

F at Risk for Pulmonary Fibrosis, a Complex Genetic Disorder. Talbert, Janet\*, Brown, Kevin K., **Kervitsky, Dolly**. National Society of Genetic Counselors Oct 2010

Familial Pulmonary Fibrosis Genetic Counseling Program: A Groundbreaking Program for Patients and Families at Risk for Pulmonary Fibrosis, a Complex Genetic Disorder. Talbert, Janet, Brown, Kevin K., **Kervitsky, Dolly**. Aspen Lung Conference Jun 2010

**IPF Clinical Research Network**, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis *N Engl J Med* 2010 Aug 12;363(7):620-8. Doi: 10.1056/NEJMoa1002110. Epub 2010 May 18

Gizinski, AM, Mascolo M, Loucks JL, **Kervitsky A**, Meehan RT, Brown, KK, Holers VM, Deane KD: Rheumatoid arthritis (RA0-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. *Clin Rheumatol.* 2009 May;28(5):611-3. doi 10.1007/s10067-009-1128-9. Epub 2009 Feb 28.

Swigris JJ, Swick J, Wamboldt FS, Sprunger D, DuBois R, Fischer A, Cosgrove GP, Frankel SK, Fernandez-Perez ER, **Kervitsky D**, Brown KK. Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. *Chest* 2009; 136(3):841-8 Epub 2009 Apr 24

Kinder, Brown, Schwarz, Ix, **Kervitsky**, King: Baseline BAL Neutrophilia Predicts Early Mortality in IPF. *Chest* 2008; 133:226-232

Kinder, Brown, McCormack, Ix, **Kervitsky**, Schwarz, King: Serum Surfactant Protein A is A Strong Predictor of Early Mortality in IPF: *Chest* 2009 Jun;135(6):1557-63. Epub 2009 Mar 2.

Boon, Bailey, Steele, Groshong, Yang, **Kervitsky**, Brown, Schwarz, Schwartz: Molecular Phenotypes Distinguish Rapid and Slow Progressors in IPF. *PLoS One.* 2009;4(4):e5134. Epub 2009 Apr 6

Gizinski, Mascolo, Loucks, **Kervitsky**, Meehan, Brown, Holers, Deane: Rheumatoid Arthritis (RA) Specific Autoantibodies in patients with ILD and the Absence of Clinically apparent Articular RA. *Clin Rheumatol.* 2009 May;28(5):611-3. Epub 2009 Feb 28

## Publications

Mary Willcox, **Alma Kervitsky**, Leslie C. Watters and Talmadge E. King, Jr.: Quantification of Cells Recovered by Bronchoalveolar Lavage, Comparison of Cytocentrifuge Preparations with the Filter Method. American Review of Respiratory Disease Vol 140 Num 4 Oct. 1989

T.E. King, KL Christopher, J Zeballos, L Watters, R Harbeck, M. Willcox, **A Kervitsky**: Bronchoalveolar Lavage, Gallium-67 Citrate (Ga) Lung Scanning and Circulating Immune Complexes (CIC) in the Staging of Idiopathic Pulmonary Fibrosis: Correlation with Physiologic and Morphologic Features; AFCR Western Section 1983

ML Willcox, **A. Kervitsky**, LC Watters, TE King: Effect of Processing on the Quantification of Cells Recovered by Bronchoalveolar Lavage: ATS abstract 1985

TE King, ML Willcox, **A Kervitsky**, LC Watters: Quantification of Cells Recovered by Bronchoalveolar Lavage (BAL): Comparison of Cytocentrifuge Preparations to the Filter Method: ATS abstract 1987

SM Aguayo, **AJ Kervitsky**, TE King: Effect of General Versus Local Anesthesia on Bronchoalveolar Lavage Cellular and Fluid Recovery in Patients with Idiopathic Pulmonary Fibrosis; ATS abstract 1989

G Raghu, CR Bozic, K Brown, D Lynch, D Center, SM Aguayo, K Lloyd, J Lull, **D Kervitsky**, DA Schwartz, and TE King Jr: Trial of Interferon Beta-1a (IFN $\beta$ -1a) in Idiopathic Pulmonary Fibrosis (IPF): Characteristics of Patients With and Without Surgical Lung Biopsy, ATS poster 2000

G Raghu, CR Bozic<sup>1</sup>, K Brown, D Lynch, D Center<sup>1</sup> SM Aguayo, F Khambatta, J Lull, **D Kervitsky**, DA Schwartz, and TE King Jr : Feasibility of a Trial of Interferon Beta – 1A (IFN b-1A) in the Treatment of Idiopathic Pulmonary Fibrosis (IPF), ATS poster 2001

AC Best, AM Lynch, CR Bozic, G Raghu, K Brown, D Center, SM Aguayo, F Khambatta, J Lull **D Kervitsky**, DA Schwartz, TE King, Jr, DA Lynch: Quantitative CT Indices in IPF: Relationship to Physiologic Impairment, ATS poster 2001